Patent ID: 11885812
Assignee: EXAGEN INC.
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 10:
11. A method for treating systemic lupus erythematosus in a human subject in need thereof, wherein the human subject is negative for systemic lupus erythematosus based on a level of double-stranded DNA antibody; the method comprising:
(a) measuring a level of erythrocyte-bound C4d (EC4d) marker, a level of B-lymphocyte-bound C4d (BC4d) marker, and a level of anti-nuclear antibody (ANA) in a blood sample obtained from the human subject;
(b) determining that the human subject has systemic lupus erythematosus based on the level of EC4d, the level of BC4d, and the level of ANA; and
(b) administering to the human subject an effective amount of cyclophosphamide, a corticosteroid, mycophenolate, methotrexate, azathioprine, leflunomide, belimumab, or hydroxychloroquine, thereby treating systemic lupus erythematosus.